What did @kekes.plot actually say?
Honestly? Not much. The transcript captured from this video is a garbled audio fragment: "You wear them shoes and back wear a wear that dress, oh." There is no substantive medical claim in the spoken content. What we do have is the caption, which states that semaglutide "can help" with weight loss and directs viewers to Freya, a telehealth platform, as a "trustworthy and reliable source" for weight loss aids.
That distinction matters. The fact-checkable content here lives in the caption, not the spoken word. The creator is making an implicit endorsement of semaglutide as a weight loss intervention and vouching for a specific commercial platform to obtain it. With 944,000 views, that endorsement carries weight whether or not the creator spelled out a clinical argument.
Does the science back this up?
On the core claim, yes. Semaglutide does help with weight loss, and the evidence is not thin. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed that adults taking 2.4mg weekly semaglutide lost an average of 14.9% of body weight over 68 weeks versus 2.4% on placebo. That is a clinically meaningful difference.
The mechanism is well understood. Semaglutide is a GLP-1 receptor agonist that slows gastric emptying and acts on hypothalamic appetite centers to reduce hunger signaling. It was originally developed for type 2 diabetes management and received FDA approval for chronic weight management under the brand name Wegovy in 2021.
- STEP 1 trial: 1961 adults, 68 weeks, 14.9% mean weight loss on semaglutide (Wilding et al., 2021, NEJM)
- STEP 4 trial found weight regain after discontinuation, meaning this is not a one-and-done treatment (Rubino et al., 2021, JAMA)
- Common side effects include nausea, vomiting, and GI distress, affecting a significant portion of users
What did they get wrong (or right)?
The caption claim that semaglutide "can help" with weight loss is accurate. Credit where it is due. The advice to use a "trustworthy and reliable source" before trying any weight loss aid is also reasonable public health messaging, even if it doubles as a promotional plug.
What is missing is context that a responsible endorsement should include. Semaglutide is a prescription medication. It is not appropriate for everyone. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 are contraindicated. The STEP trials enrolled specific populations, and real-world results vary.
The endorsement of Freya specifically also cannot be independently verified from this video alone. Telehealth platforms vary significantly in how they screen patients, what form of semaglutide they prescribe (brand-name versus compounded), and what follow-up they provide. A vague "trustworthy" label is not the same as clinical vetting.
What should you actually know?
If you are considering semaglutide for weight management, the evidence supports its effectiveness, but the details matter a lot. First, compounded semaglutide, which many telehealth platforms have been prescribing, is not equivalent to FDA-approved Wegovy or Ozempic. The FDA has flagged safety concerns around compounded versions, and the American Society of Health-System Pharmacists has raised quality control issues.
Second, cost and access are real barriers. Wegovy lists at over $1,300 per month without insurance. Telehealth platforms sometimes offer compounded alternatives at lower prices, but patients should understand exactly what they are getting.
Third, stopping semaglutide typically leads to weight regain. The STEP 4 trial showed participants regained about two-thirds of lost weight within a year of discontinuation. This is a long-term treatment consideration, not a short course.
- Always confirm a prescriber reviews your full medical history before starting
- Ask explicitly whether you are receiving FDA-approved semaglutide or a compounded version
- Report side effects, particularly severe GI symptoms or vision changes, to your provider immediately